HematologyNeurologyGeneticsGenetic DisorderCentral Nervous SystemBiotechnologyScience and EngineeringSoftware
Description
BioMarin Pharmaceutical Inc. (BioMarin) operates as a global biotechnology company.
Recent Developments
In December 2025, the company entered into a definitive agreement to acquire Amicus Therapeutics, Inc. (Amicus), a publicly traded global biotec…
Analysis
Quality compounder
BioMarin Pharmaceutical Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.
On valuation, the picture is expensive. The owner-earnings multiple stands at 46.9×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 18% a year, against analyst forecasts of 29%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is sturdy. The company scores 8/20 on our value-creation score: creating some value.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Feb 2026100
100
2026
All-time high
100
Jun 2026
All-time low
97
Mar 2026
Average rank
99
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
94
—
—
—
Price/Earnings
7
—
—
—
Price/Book
58
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
70
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.